{
    "clinical_study": {
        "@rank": "147838", 
        "arm_group": {
            "arm_group_label": "HIPEC surgery with chemotherapy", 
            "arm_group_type": "Experimental", 
            "description": "3 courses of pre-operative chemotherapy: carboplatin AUC = 5 IV + paclitaxel 175 mg/m2 IV every 3 weeks\nDebulking surgery\nHIPEC with cisplatin 50 mg/m2 intraperitoneally at the end of surgery\n3 courses of post-operative chemotherapy: carboplatin AUC = 5 IV + paclitaxel 175 mg/m2 IV every 3 weeks"
        }, 
        "brief_summary": {
            "textblock": "First line treatment for advanced ovarian carcinoma hyperthermic intraperitoneal\n      chemotherapy (HIPEC) after optimal debulking."
        }, 
        "brief_title": "Feasibility Study of HIPEC for Patients With Stage III or Only Pleural Stage IV Ovarian Carcinoma in First Line Therapy", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Ovarian Carcinoma", 
            "Fallopian Tube Carcinoma", 
            "Primary Peritoneal Carcinoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Ovarian Neoplasms", 
                "Neoplasms, Glandular and Epithelial", 
                "Fallopian Tube Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Addition of HIPEC to the standard first line treatment of ovarian carcinoma."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  stage III or only pleural stage IV ovarian carcinoma first line treatment\n\n        Exclusion Criteria:\n\n          -  incomplete surgery poor performance status bad general condition"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01709487", 
            "org_study_id": "HIPEC"
        }, 
        "intervention": {
            "arm_group_label": "HIPEC surgery with chemotherapy", 
            "description": "HIPEC with cisplatin 50 mg/m2 intraperitoneally at the end of surgery", 
            "intervention_name": "HIPEC", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "HIPEC", 
            "ovarian carcinoma", 
            "Bordet"
        ], 
        "lastchanged_date": "November 20, 2013", 
        "location": [
            {
                "contact": {
                    "email": "joseph.kerger@bordet.be", 
                    "last_name": "Joseph Kerger, M.D.", 
                    "phone": "+3225413262"
                }, 
                "contact_backup": {
                    "email": "lionel.cordier@bordet.be", 
                    "last_name": "Lionel Cordier", 
                    "phone": "+3225413213"
                }, 
                "facility": {
                    "address": {
                        "city": "Brussels", 
                        "country": "Belgium", 
                        "zip": "1000"
                    }, 
                    "name": "Institut Jules Bordet"
                }, 
                "investigator": {
                    "last_name": "Joseph Kerger, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "fgoffin@chu.ulg.ac.be", 
                    "last_name": "Fr\u00e9d\u00e9ric Goffin, M.D.", 
                    "phone": "+3242257543"
                }, 
                "facility": {
                    "address": {
                        "city": "Li\u00e8ge", 
                        "country": "Belgium", 
                        "zip": "4000"
                    }, 
                    "name": "Hopital de la Citadelle"
                }, 
                "investigator": {
                    "last_name": "Fr\u00e9d\u00e9ric Goffin, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "1", 
        "official_title": "Feasibility Study of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Patients With Stage III or Only Pleural Stage IV Ovarian Carcinoma in First Line Therapy", 
        "overall_official": [
            {
                "affiliation": "Institut Jules Bordet, Brussels, Belgium.", 
                "last_name": "Joseph Kerger, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hopital de la Citadelle, Li\u00e8ge, Belgium.", 
                "last_name": "Fr\u00e9d\u00e9ric Goffin, M.D.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Belgium: Federal Agency for Medicinal Products and Health Products", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "We will record the mortality rate of our interventions: 3 cycles of pre-operative chemotherapy, surgery and HIPEC, 3 cycles of post-operative chemotherapy.", 
            "measure": "mortality rate", 
            "safety_issue": "Yes", 
            "time_frame": "24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01709487"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "progression free survival", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }
        ], 
        "source": "Jules Bordet Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Jules Bordet Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2010", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}